Jason Rhodes is a Partner at Atlas Venture. He is the Chairman and previously founding Chief Executive Officer of Dyne Therapeutics, Rectify Pharmaceuticals, and Generation Bio. Mr. Rhodes is also on the Boards of AAVantgarde Bio, Be Biopharma, and K36. He was the chairman and founding Chief Executive Officer of Disarm Therapeutics and was previously on the boards of Third Harmonic Bio, Replimune, and Bicycle Therapeutics. Prior to joining Atlas Venture, Rhodes was President of Epizyme (NASDAQ), where he charted the company’s strategic course from a private, research-stage business into the clinic and through a successful IPO in 2013. Prior to Epizyme, he led business development at Alnylam (NASDAQ). Before Alnylam, he was a Founder and Partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments. Rhodes received his BA degree from Yale University and his MBA from the Wharton School of the University of Pennsylvania. He is a member of the advisory board of the Harvard Institute for RNA Medicine, the BIDMC Board of Overseers, the Blavatnik Fund at Yale University, and the Berklee College of Music Presidential Advisory Council.